Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome
Objective. Polycystic ovary syndrome (PCOS) is associated with obesity and insulin resistance (IR), key features of nonalcoholic steatohepatitis (NASH). Cytokeratin 18 fragments (M30) have been established as a serum marker for NASH. The insulin sensitizer metformin improves hepatic IR. This study e...
Saved in:
Main Authors: | Susanne Tan, Nils Vollmar, Sven Benson, Jan-Peter Sowa, Lars P. Bechmann, Guido Gerken, Dagmar Fuhrer, Ali Canbay |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2015/254169 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Update on the therapeutic role of metformin in the management of polycystic ovary syndrome: Effects on pathophysiologic process and fertility outcomes
by: Kerstin MG Brand, et al.
Published: (2025-01-01) -
Prevalence and factors associated with non-alcoholic fatty liver disease among women with polycystic ovary syndrome
by: Maria Elisa Franciscatto, et al.
Published: (2025-01-01) -
Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
by: Ali Mahmoudi, et al.
Published: (2022-01-01) -
Expression of SET Protein in the Ovaries of Patients with Polycystic Ovary Syndrome
by: Xu Boqun, et al.
Published: (2013-01-01) -
Cannabinoid Receptor 1 Gene Polymorphisms and Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome and in Healthy Controls
by: Justyna Kuliczkowska Plaksej, et al.
Published: (2014-01-01)